
Gabby Migliara is a senior manager of public affairs at PhRMA focusing on the cost and value of medicines. She previously worked with the U.S. Census Bureau on marketing and communications for the 2020 Census campaign. Outside the office, Gabby enjoys trying new restaurants, hanging with her cat and exploring DC neighborhoods.
Recent Posts
Why drug importation is bad for Americans

Drug importation schemes are dangerous and have significant negative consequences for both individuals and our health care system. Importation refers to when governments or individuals circumvent the...
Read More
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. We’ve made...
Read More
Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...
Read More
Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

Medicare Part D provides prescription drug coverage for our nation’s seniors and Americans with disabilities. These beneficiaries can opt to enroll in Part D and pick from a variety of plans offered....
Read More
New analysis confirms hospitals markup prices for oncology therapies

A recent study from The Journal of the American Medical Association (JAMA) examined 61 hospitals using data made public under new requirements from a recent price transparency regulation. The...
Read More
Veterans Affairs 101: Three charts show how the VA system differs from Medicare

The U.S. Department of Veterans Affairs (VA) primarily provides medical coverage for veterans who have experienced service-related disabilities. Its unique system was developed to meet the targeted...
Read More
ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...
Read More
New report: To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and the health system

A new study from the Employee Benefit Research Institute (EBRI) compared the difference in price for 72 physician-administered outpatient medicines – representing 73% of medicine spending – depending...
Read More
PhRMA releases 2021 industry profile

Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access and affordability. The Profile has told the story of...
Read More
What they’re saying: Patient advocates want to protect Medicare from government interference

For seniors and people with disabilities, Medicare Parts B and D provide important access to lifesaving medicines. Unfortunately, some in Congress are proposing changes to Medicare under the guise of...
Read More